Lambert-Eaton myasthenic syndrome

Area of Science:

• Neuroimmunology
• Oncology
• Molecular Biology

Background:

• Lambert-Eaton myasthenic syndrome (LEMS) is frequently associated with small cell lung cancer (65% of cases).
• LEMS is characterized by impaired acetylcholine release from nerve terminals, affecting neuromuscular transmission.
• The condition exhibits features suggestive of an autoimmune etiology, including associations with other autoimmune diseases and specific genetic markers.

Purpose of the Study:

• To investigate the autoimmune mechanisms underlying Lambert-Eaton myasthenic syndrome.
• To identify the specific targets of the autoantibodies involved in LEMS.
• To elucidate the physiological consequences of these autoantibodies on neurotransmitter release.

Main Methods:

• Passive transfer of LEMS patient IgG to mice to replicate electrophysiological features.
• Measurement of acetylcholine release and quantal content in animal models.
• Complement (C5) deficiency studies in mice.
• Electron microscopic freeze fracture analysis of nerve terminals.

Main Results:

• LEMS IgG successfully induced characteristic electrophysiological changes in mice.
• A significant decrease in quantal content of acetylcholine release was observed, correlating with IgG levels.
• Studies suggest a functional loss of approximately 40% of calcium channels.
• Electron microscopy revealed a reduced number of active zone particles, believed to be calcium channels, in affected animals.

Conclusions:

• LEMS is likely caused by IgG antibodies targeting nerve terminal calcium channels or closely associated structures.
• In cancer-associated LEMS, antibodies may initially target tumor cell determinants, with cross-reactivity leading to LEMS.
• The findings support a humorally mediated autoimmune disorder affecting neuromuscular transmission via calcium channel dysfunction.